Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Persistence of antidepressant treatment effects in a pharmacotherapy plus psychotherapy trial for active injection drug users.
The objective of this study was to determine if combined psychotherapy and pharmacotherapy reduces reported depressive symptoms compared to an assessment only condition for active drug injectors over nine months . Using a r and omized controlled trial at an outpatient academic research office , the research ers applied psychotherapy ( eight sessions of cognitive behavioral therapy ) plus pharmacotherapy ( citalopram ) to active injection drug users with a DSM-IV diagnosis of major depression , dysthymia , substance-induced mood disorder with symptoms persisting for at least three months , or major depression plus dysthymia , and a Modified Hamilton Rating Scale for Depression ( MHRSD ) score greater than 13 . The MHRSD scale scores were then assessed at the completion of three , six , and nine months . Participants ( n = 109 ) were 64 % male and 82 % Caucasian , with a mean baseline MHRSD score of 20.7 . Depression subtypes included major depression only ( 63 % ) , substance-induced depression ( 17 % ) , and double-depression ( 17 % ) .  Study retention at nine months was 89 % . At the completion of three months of acute treatment , 26 % of combined treatment patients ( n = 53 ) , compared to 12 % of control patients ( n = 56 ) , were in remission ( p = .047 ) . At both six and nine months , the between-group differences in remission rates and mean MHRSD scores were insignificant , although the overall mean MHRSD score decreased from baseline ( p < .01 ) . At all follow-up assessment s , depression remission was significantly associated with lower heroin use . Among active drug injectors diagnosed with depression , symptoms decline over time . Combined treatment is superior to an assessment -only condition in depression remission rates at the end-of-treatment , but this difference does not persist
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .